In this retrospective study, we used human aldose reductase inhibitors to demonstrate an active learning workflow that prioritizes molecules from a large pool of bioisostere replacements generated by ...

central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia." According to the Company, "[t]he CRL indicates that the FDA completed its ...

The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases, including Galactosemia.

The Company's lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases, including Galactosemia.

Govorestat is an aldose reductase inhibitor (ARI) designed to replace the enzyme that is deficient in people with the disorder, restoring their ability to metabolise galactose. "We are ...

AT-001 works by preventing an enzyme, aldose reductase, from breaking down glucose into another type of sugar, called sorbitol, that can damage heart tissue by causing the heart muscle to stiffen ...

APPLIED THERAPEUTICS, INC. : William Blair & Co. abaisse son opinion à neutre 23/12 ZM APPLIED THERAPEUTICS, INC. : RBC Capital Markets est neutre sur le titre 20/12 ZM Applied Therapeutics nomme ...

Working with a diverse panel of field-grown rice accessions, this valuable study measures changes in transcript abundance, tests for patterns of selection on gene expression, and maps the genetic ...

The roots of A. continentalis were purchased in a local market in Seoul, Korea, in May 2020. All solvents for extraction were of low particulate grade and purchased from SK chemicals (Ulsan, Korea).

Objective: Intraplaque neovascularization is a marker of plaque vulnerability and is used to predict the risk of future vascular events in patients with symptomatic carotid stenosis; however, its ...